Exelixis EXEL Business Segments — Drug discovery
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept exel:DrugDiscoveryCosts.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's business segments — drug discovery.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's business segments — drug discovery?
- Exelixis (EXEL) reported business segments — drug discovery of $19.48M in Q1 2026.
- How has Exelixis's business segments — drug discovery changed year-over-year?
- Exelixis's business segments — drug discovery increased by 6.7% year-over-year, from $18.25M to $19.48M.
- What is the long-term trend for Exelixis's business segments — drug discovery?
- Over 3 years (2022 to 2025), Exelixis's business segments — drug discovery has grown at a -28.9% compound annual growth rate (CAGR), from $249.71M to $89.93M.
- What does business segments — drug discovery mean?
- Spending on early-stage research to find and develop new drug candidates.
- How do you interpret business segments — drug discovery?
- Higher spending indicates a commitment to future innovation, though it may temporarily depress current profitability.
- How does business segments — drug discovery compare across companies?
- Comparable to 'Early-stage R&D' or 'Discovery Research' expenses at other biotech firms.